#Outset medical careers full

This team represents a full suite of C-suite executives capable of addressing strategic, operational, financial, and organizational issues, which we expect will enable us to take a highly differentiated approach to any deal. “Atmas Health will draw on the team’s decades of experience and strengths within medical technology, life science tools and diagnostics sectors. We expect to maximize the potential of this team by leveraging our entire global Carlyle platform to support Atmas in identifying and evaluating opportunities.” “We have a long history investing in medical products and instruments, and we believe Atmas Health presents an excellent opportunity to extend that experience. “Carlyle is thrilled to be partnering with this team of exceptional executives that has a proven expertise in running healthcare businesses,” said Steve Wise, Carlyle’s Global Head of Healthcare.

“We look forward to working with the Carlyle team and believe Carlyle’s deep healthcare experience and global resources will open up opportunities to find assets with the right fit.” We believe these are areas in which our collective experiences can be leveraged to build real value,” said Kieran Gallahue. “We are excited to pursue complex transactions spanning any number of deal archetypes from buy-and-build to carve-outs to founder-led businesses to take-privates, focusing on assets with strong leadership positions within markets benefiting from long-term secular tailwinds. He has collaborated with Carlyle on hundreds of diligence processes across the globe and partnered with Carlyle portfolio companies on numerous value creation initiatives. He is a former Partner at PwC, specializing in M&A transaction diligence and post deal value capture and integration projects. Jim Prutow has more than 30 years of experience as a healthcare executive and consultant on many successful private equity-backed acquisitions. Jim also currently serves on the board of Outset Medical (NASDAQ: OM), Acutus Medical (NASDAQ: AFIB), Integer Holdings (NYSE: ITGR), and Orthofix (NASDAQ: OFIX). As the former CFO of CareFusion from 2010 until its sale in 2015, he worked closely with Kieran on a number of growth and cost improvement initiatives.

Jim Hinrichs is the former CFO of Alere from 2015 until its sale to Abbott for $8 billion in 2017. He is also the former CEO and director of ResMed from 2008 to 2011 and previously served on the boards of Intersect ENT, Arena Pharmaceuticals, and Volcano Corporation. Kieran currently serves on several company boards, including Edwards Lifesciences (NYSE:EW) and Envista (NYSE: NVST). During his tenure at CareFusion, he led key value creation initiatives at the company including portfolio optimization, investments in innovation, and cost improvement. Kieran Gallahue is the former Chairman and CEO of CareFusion from 2011 until its sale to Becton, Dickinson and Company (NYSE: BDX) for over $12 billion in 2015. The team of executives has served in numerous leadership roles within the healthcare industry with significant experience evaluating, acquiring, and leading public and private healthcare companies within several sectors. Atmas Health will receive investment from funds managed by Carlyle alongside investment from Kieran Gallahue, Jim Hinrichs, and Jim Prutow. Atmas Health, headquartered in Park City, Utah, will focus on acquiring healthcare assets within the medical technology and products, life science tools and diagnostics sectors as part of its strategy to build a market-leading healthcare business. New York, New York and Park City, Utah – SeptemGlobal investment firm Carlyle (NASDAQ: CG) announced today the formation of Atmas Health in partnership with long-time healthcare executives Kieran Gallahue, Jim Hinrichs, and Jim Prutow and Carlyle’s Global Healthcare team.

Outset medical careers